Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Related Clinical Trial
Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Official Title

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Brief Summary

      The purpose of this study is to determine the efficacy of Droxidopa for the treatment of
      fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS). This is a
      randomized, placebo-controlled, double-blind clinical trial for 3 months where half the
      subjects will receive placebo and the other half will receive Droxidopa. Following this will
      be a wash-out period of 7 days and then all subjects will receive Droxidopa for 3 months
      during the open-label phase.
    

Detailed Description

      Parkinsonism, is a group of symptoms seen in several diseases, including Parkinson's Disease.
      In Parkinsonism, a patient may become stiff, have smaller and slower movements, develop a
      tremor (shaking of the arms or legs), have decreased facial expression, and a softer voice.

      Fatigue is a common symptom that causes suffering and stress in diseases that affect the
      brain. Over 50% of patients with Parkinsonism report fatigue as one of their top three
      symptoms that make their life more difficult. Currently, there are no evidence-based
      guidelines for treating fatigue in Parkinson's Disease, and no effective medications or
      therapeutic modalities exist for fatigue symptoms in patients with Parkinson's Disease.

      Droxidopa (also known by the trade name NORTHERA) is a safe and well tolerated medication
      which has been approved in USA for the treatment of orthostatic dizziness or light headedness
      in patients with a clinical diagnosis of symptomatic Neurogenic Orthostatic Hypotension
      associated with primary autonomic failure (Parkinson's Disease and Multiple System Atrophy),
      Dopamine Beta Hydroxylase Deficiency, or Non Diabetic Autonomic Neuropathy.

      Fatigue may be due to diminished levels of norepinephrine in Parkinson's Disease. The locus
      coeruleus, one of the major sources of norepinephrine, is affected during the preclinical
      phase of Parkinson's Disease during stage 2 of Braak pathology staging. Norepinephrine is the
      final metabolite of dopamine, therefore by adding exogenous norepinephrine, it may be
      possible to control some of the motor and non-motor symptoms of Parkinsonism. Norepinephrine
      is the final metabolite of droxidopa, and it is still unclear if it passes the blood-brain
      barrier. This pilot study is to measure the efficacy and safety of droxidopa in Parkinsonism
      patients with fatigue.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Efficacy of Droxidopa on fatigue in subjects with Parkinsonism as determined by completion of Visual Analogue Fatigue Scale (VAFS)

Secondary Outcome

 Efficacy of Droxidopa on motor and non-motor symptoms of Parkinsonism as determined by the Unified Parkinson's Disease Rating Scale (UPDRS)

Condition

Parkinson Disease

Intervention

Droxidopa

Study Arms / Comparison Groups

 Droxidopa
Description:  The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

32

Start Date

December 2021

Completion Date

July 1, 2023

Primary Completion Date

July 1, 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Age of 50 years or older.

          -  Clinical diagnosis of Parkinsons Disease or Atypical Parkinsonism (including multiple
             system atrophy (MSA), PSP)

          -  Fluent in English

          -  Reported fatigue and must have a mean VAFS score of 4 or more at baseline

          -  Written informed consent

        Exclusion Criteria:

          -  Inability to understand or cooperate with study procedures

          -  Alcohol or substance use disorder within the past 12 months (as per Diagnostic and
             Statistical Manual of Mental Disorders (DSM-5) criteria)

          -  Women who are pregnant or breastfeeding

          -  Women of childbearing potential (WOCP) as indicated by one of the following:

          -  Sustained supine hypertension greater than or equal to 180 mmHg systolic or 110 mmHg
             diastolic. Sustained is defined as the average of 3 observations each at least 10
             minutes apart with the patient having been supine and at rest for at least 5 minutes
             prior to each measurement

          -  Untreated closed angle glaucoma

          -  Diagnosis of hypertension that requires treatment with antihypertensive medications

          -  Any significant uncontrolled cardiac arrhythmia

          -  History of myocardial infarction, within the past 2 years

          -  Current unstable angina

          -  Congestive heart failure (NYHA Class 3 or 4)

          -  Diabetic autonomic neuropathy

          -  History of cancer within the past 2 years other than a successfully treated,
             non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in
             situ

          -  Gastrointestinal condition that may affect the absorption of Investigational Medicinal
             Product (e.g. ulcerative colitis, gastric bypass)

          -  Any major surgical procedure within 30 days prior to the first titration visit.

          -  Currently receiving any investigational drug or have received an investigational drug
             within 28 days prior to the first titration visit

          -  Any condition or laboratory test result, which in the Investigator's judgment, might
             result in an increased risk to the patient, or would affect their participation in the
             study

          -  Dementia or non-treated depression

          -  Subjects who have a mean VAFS score of less than 4 at baseline

          -  Vulnerable populations

          -  Uncontrolled intercurrent illnesses including, but not limited to severe lung disease,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, symptomatic cardiac arrhythmia, and situations that would limit compliance
             with study requirements will be excluded

          -  Orthostatic hypotension (OH)
      

Gender

All

Ages

50 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Khashayar Dashtipour, M.D. Ph.D., 909-558-2037, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03446807

Organization ID

5170406


Responsible Party

Sponsor

Study Sponsor

Loma Linda University

Collaborators

 H. Lundbeck A/S

Study Sponsor

Khashayar Dashtipour, M.D. Ph.D., Principal Investigator, Loma Linda University Health


Verification Date

August 2021